Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $1.42.

  • CorMedix's EPS (Basic) rose 294000.0% to $1.42 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.27, marking a year-over-year increase of 41527.78%. This contributed to the annual value of -$0.3 for FY2024, which is 6653.17% up from last year.
  • CorMedix's EPS (Basic) amounted to $1.42 in Q3 2025, which was up 294000.0% from $0.29 recorded in Q2 2025.
  • In the past 5 years, CorMedix's EPS (Basic) ranged from a high of $1.42 in Q3 2025 and a low of -$0.25 during Q2 2023
  • Moreover, its 5-year median value for EPS (Basic) was -$0.18 (2022), whereas its average is -$0.02.
  • Per our database at Business Quant, CorMedix's EPS (Basic) crashed by 5833.33% in 2022 and then skyrocketed by 294000.0% in 2025.
  • Quarter analysis of 5 years shows CorMedix's EPS (Basic) stood at -$0.21 in 2021, then grew by 4.76% to -$0.2 in 2022, then increased by 15.0% to -$0.17 in 2023, then skyrocketed by 234.53% to $0.23 in 2024, then surged by 520.88% to $1.42 in 2025.
  • Its EPS (Basic) stands at $1.42 for Q3 2025, versus $0.29 for Q2 2025 and $0.32 for Q1 2025.